Regenxbio
RGNX
89 hedge funds and large institutions have $705M invested in Regenxbio in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 20 closing their positions.
332% more call options, than puts
Call options by funds: $2.12M | Put options by funds: $491K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
112% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 17
57% more capital invested
Capital invested by funds: $448M → $705M (+$257M)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
3% more funds holding
Funds holding: 86 → 89 (+3)
4.25% less ownership
Funds ownership: 73.51% → 69.26% (-4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.38M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$6.49M |
| 3 |
RI
RTW Investments
New York
|
+$5.99M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$5.06M |
| 5 |
BlackRock
New York
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$23.4M |
| 2 |
Millennium Management
New York
|
-$7.21M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.14M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.19M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.36M |
RGNX Hedge Fund Activity: Q3 2017 in Review
89 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2017, worth a combined $705M — up 57% from $448M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RGNX positions and 20 closed out — a net gain of 3 holders — while 36 added to existing stakes and 17 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $23.4M.
- 89 institutional investors held Regenxbio (RGNX) as of Q3 2017, up from 86 in Q2 2017.
- Funds reported $705M of Regenxbio stock for Q3 2017, up 57% quarter-over-quarter.
- 23 funds opened new Regenxbio positions in Q3 2017 and 20 closed out, a net change of +3 holders.
- The largest Regenxbio buyer in Q3 2017 was Farallon Capital Management, an estimated $9.38M added.
- The largest Regenxbio seller in Q3 2017 was Bain Capital Public Equity Management, an estimated $23.4M sold.
Based on aggregated 13F filings for Q3 2017.